Literature DB >> 11150912

Thrombospondin-1 and -2 in node-negative breast cancer: correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis.

G Gasparini1, M Toi, E Biganzoli, R Dittadi, M Fanelli, A Morabito, P Boracchi, M Gion.   

Abstract

OBJECTIVE: Thrombospondins (TSP(s)) are a multigene family of five secreted glycoproteins involved in the regulation of cell proliferation, adhesion and migration. Two members of the TSP family, namely TSP-1 and TSP-2, are also naturally occurring inhibitors of angiogenesis. The aim of the present study was to determine the prognostic significance of the determination of TSP-1 and -2 and their correlation with the angiogenic peptides vascular endothelial growth factor (VEGF) and thymidine phosphorylase (TP), as well as with other biological and clinicopathological features investigated.
METHODS: We evaluated a series of 168 women with node-negative breast cancer with a median follow-up period of 66 months, not treated with adjuvant therapy. The cytosolic levels of TSP-1 and -2 were determined in the primary tumour by a commercially available immunometric assay.
RESULTS: We found that 166 tested tumours had measurable levels of TSP-1 and -2 protein (median value 5.978, range 0.579-31.410 ng/mg of protein). On the basis of Spearman's rank correlation coefficient, a weak inverse association of TSP-1 and -2 with tumour size and cathepsin D was found. Moreover, principal component analysis on ranks evidenced a poor association between TSP-1 and -2, VEGF and TP. The results of the clinical outcome were analysed by both univariate and multivariate [for relapse-free survival (RFS) only]) Cox regression models. TSP-1 and -2 were not significant prognostic factors in univariate analysis for either RFS (p = 0.427) or overall survival (p = 0.069). To investigate the 'angiogenic balance hypothesis', bivariate analyses were performed to investigate the interactions of TSP-1 and -2 with VEGF, TP or p53, but none were included in the selected models. Finally, in multivariate analysis for RFS a baseline model, previously defined in a larger case series and inclusive of VEGF, TP and their interaction was adopted. It was highly significant (p = 0.002, Harrell c statistic value of 0.703); but when TSP-1 and -2 were added, their contribution was negligible (p = 0.731, Harrell c statistic value of 0.705).
CONCLUSIONS: The results of this study suggest that TSP-1 and -2 do not provide additional prognostic contribution to the joint effects of VEGF and TP. In the series of node-negative breast cancer patients investigated, determination of the angiogenic peptides VEGF and TP gave significant prognostic information. On the contrary, TSP-1 and -2, potential naturally occurring negative regulators of angiogenesis, lacked prognostic value.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11150912     DOI: 10.1159/000055300

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  8 in total

1.  sFRP-1 binds via its netrin-related motif to the N-module of thrombospondin-1 and blocks thrombospondin-1 stimulation of MDA-MB-231 breast carcinoma cell adhesion and migration.

Authors:  Gema Martin-Manso; Maria J Calzada; Yoshiro Chuman; John M Sipes; Charles P Xavier; Vladimir Wolf; Svetlana A Kuznetsova; Jeffrey S Rubin; David D Roberts
Journal:  Arch Biochem Biophys       Date:  2011-03-21       Impact factor: 4.013

2.  p53-responsive miR-194 inhibits thrombospondin-1 and promotes angiogenesis in colon cancers.

Authors:  Prema Sundaram; Stacy Hultine; Lauren M Smith; Michael Dews; Jamie L Fox; Dauren Biyashev; Janell M Schelter; Qihong Huang; Michele A Cleary; Olga V Volpert; Andrei Thomas-Tikhonenko
Journal:  Cancer Res       Date:  2011-10-25       Impact factor: 12.701

3.  The association between vascular endothelial growth factor expression in invasive breast cancer and survival varies with intrinsic subtypes and use of adjuvant systemic therapy: results from the Nurses' Health Study.

Authors:  Ying Liu; Rulla M Tamimi; Laura C Collins; Stuart J Schnitt; Hannah L Gilmore; James L Connolly; Graham A Colditz
Journal:  Breast Cancer Res Treat       Date:  2011-03-09       Impact factor: 4.872

4.  Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon?

Authors:  Olga Golubnitschaja; Kristina Yeghiazaryan; Vincenzo Costigliola; Daniela Trog; Michael Braun; Manuel Debald; Walther Kuhn; Hans H Schild
Journal:  EPMA J       Date:  2013-02-19       Impact factor: 6.543

5.  Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components.

Authors:  E Ioachim; M C Michael; M Salmas; K Damala; E Tsanou; M M Michael; V Malamou-Mitsi; N E Stavropoulos
Journal:  BMC Cancer       Date:  2006-05-29       Impact factor: 4.430

Review 6.  Human expression patterns: qualitative and quantitative analysis of thrombospondin-1 under physiological and pathological conditions.

Authors:  Chen Zhao; Jeffrey S Isenberg; Aleksander S Popel
Journal:  J Cell Mol Med       Date:  2018-02-14       Impact factor: 5.310

7.  Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status.

Authors:  Jessica Wang-Rodriguez; Virginia Urquidi; Amber Rivard; Steve Goodison
Journal:  Breast Cancer Res       Date:  2003-07-09       Impact factor: 6.466

8.  The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy.

Authors:  P Manders; L V A M Beex; V C G Tjan-Heijnen; J Geurts-Moespot; T H Van Tienoven; J A Foekens; C G J Sweep
Journal:  Br J Cancer       Date:  2002-09-23       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.